{"entity":{"type":"insider","cik":"0001709418","url":"/insider/0001709418","json_url":"/insider/0001709418.json","name":"Stalfort John A III","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":10,"n_filings":7,"first":"2018-12-21","last":"2024-11-26","span_basis":"filed_date"},"name_variants":[{"name":"Stalfort John A III","source":"filing","n_filings":4,"first_seen":"2021-07-08","last_seen":"2024-11-26"},{"name":"Stalfort Sean","source":"filing","n_filings":3,"first_seen":"2018-12-21","last_seen":"2020-08-17"}],"transactions":[{"id":2280076,"accession":"0001415889-24-027710","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-027710","line_url":"/filing/0001415889-24-027710#line-1","is_derivative":false,"issuer_cik":"0001660334","issuer_name":"Verrica Pharmaceuticals Inc.","issuer_ticker":"VRCA","issuer_name_source":null,"issuer_url":"/issuer/0001660334","owner_cik":"0001709418","owner_name":"Stalfort John A III","owner_display_name":"Stalfort John A III","owner_url":"/insider/0001709418","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1123595.0,"shares_display":"1,123,595","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":1823800.0,"shares_owned_after_display":"1,823,800","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-22","filed_date":"2024-11-26","scope":"insider"},{"id":8222006,"accession":"0001209191-23-046152","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-046152","line_url":"/filing/0001209191-23-046152","is_derivative":false,"issuer_cik":"0001709418","issuer_name":"Taysha Gene Therapies, Inc.","issuer_ticker":"TSHA","issuer_name_source":null,"issuer_url":"/issuer/0001709418","owner_cik":"0001709418","owner_name":"Stalfort John A III","owner_display_name":"Stalfort John A III","owner_url":"/insider/0001709418","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":777778.0,"shares_display":"777,778","price_per_share":0.9,"price_display":"0.90","price_state":"stated","total_value":700000.2,"total_display":"700,000.20","total_whole":"700,000","shares_owned_after":999381.0,"shares_owned_after_display":"999,381","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-16","filed_date":"2023-08-16","scope":"insider","n_lines":2},{"id":6373666,"accession":"0001209191-22-040591","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-040591","line_url":"/filing/0001209191-22-040591#line-1","is_derivative":false,"issuer_cik":"0001660334","issuer_name":"Verrica Pharmaceuticals Inc.","issuer_ticker":"VRCA","issuer_name_source":null,"issuer_url":"/issuer/0001660334","owner_cik":"0001709418","owner_name":"Stalfort John A III","owner_display_name":"Stalfort John A III","owner_url":"/insider/0001709418","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":238095.0,"shares_display":"238,095","price_per_share":2.1,"price_display":"2.10","price_state":"stated","total_value":499999.5,"total_display":"499,999.50","total_whole":"500,000","shares_owned_after":700205.0,"shares_owned_after_display":"700,205","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-05","filed_date":"2022-07-05","scope":"insider"},{"id":4228799,"accession":"0001209191-21-046030","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-046030","line_url":"/filing/0001209191-21-046030#line-3","is_derivative":false,"issuer_cik":"0001576885","issuer_name":"Acumen Pharmaceuticals, Inc.","issuer_ticker":"ABOS","issuer_name_source":null,"issuer_url":"/issuer/0001576885","owner_cik":"0001709418","owner_name":"Stalfort John A III","owner_display_name":"Stalfort John A III","owner_url":"/insider/0001709418","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":35000.0,"shares_display":"35,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":560000.0,"total_display":"560,000.00","total_whole":"560,000","shares_owned_after":172324.0,"shares_owned_after_display":"172,324","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-06","filed_date":"2021-07-08","scope":"insider"},{"id":3046476,"accession":"0001209191-20-046963","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-046963","line_url":"/filing/0001209191-20-046963#line-2","is_derivative":false,"issuer_cik":"0001660334","issuer_name":"Verrica Pharmaceuticals Inc.","issuer_ticker":"VRCA","issuer_name_source":null,"issuer_url":"/issuer/0001660334","owner_cik":"0001709418","owner_name":"Stalfort Sean","owner_display_name":"Stalfort Sean","owner_url":"/insider/0001709418","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15700.0,"shares_display":"15,700","price_per_share":6.38,"price_display":"6.38","price_state":"stated","total_value":100166.0,"total_display":"100,166.00","total_whole":"100,166","shares_owned_after":462110.0,"shares_owned_after_display":"462,110","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-14","filed_date":"2020-08-17","scope":"insider"},{"id":3046474,"accession":"0001209191-20-046963","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-046963","line_url":"/filing/0001209191-20-046963#line-1","is_derivative":false,"issuer_cik":"0001660334","issuer_name":"Verrica Pharmaceuticals Inc.","issuer_ticker":"VRCA","issuer_name_source":null,"issuer_url":"/issuer/0001660334","owner_cik":"0001709418","owner_name":"Stalfort Sean","owner_display_name":"Stalfort Sean","owner_url":"/insider/0001709418","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15550.0,"shares_display":"15,550","price_per_share":6.45,"price_display":"6.45","price_state":"stated","total_value":100297.5,"total_display":"100,297.50","total_whole":"100,298","shares_owned_after":446410.0,"shares_owned_after_display":"446,410","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-13","filed_date":"2020-08-17","scope":"insider"},{"id":8411146,"accession":"0001209191-19-002675","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-002675","line_url":"/filing/0001209191-19-002675","is_derivative":false,"issuer_cik":"0001660334","issuer_name":"Verrica Pharmaceuticals Inc.","issuer_ticker":"VRCA","issuer_name_source":null,"issuer_url":"/issuer/0001660334","owner_cik":"0001709418","owner_name":"Stalfort Sean","owner_display_name":"Stalfort Sean","owner_url":"/insider/0001709418","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9221.0,"shares_display":"9,221","price_per_share":10.45287712829411,"price_display":"10.45","price_state":"stated","total_value":96385.98,"total_display":"96,385.98","total_whole":"96,386","shares_owned_after":429660.0,"shares_owned_after_display":"429,660","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-07","filed_date":"2019-01-07","scope":"insider","n_lines":2},{"id":6297075,"accession":"0001209191-18-063954","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-063954","line_url":"/filing/0001209191-18-063954#line-1","is_derivative":false,"issuer_cik":"0001685071","issuer_name":"Dova Pharmaceuticals Inc.","issuer_ticker":"DOVA","issuer_name_source":null,"issuer_url":"/issuer/0001685071","owner_cik":"0001709418","owner_name":"Stalfort Sean","owner_display_name":"Stalfort Sean","owner_url":"/insider/0001709418","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":31000.0,"shares_display":"31,000","price_per_share":6.26,"price_display":"6.26","price_state":"stated","total_value":194060.0,"total_display":"194,060.00","total_whole":"194,060","shares_owned_after":635665.0,"shares_owned_after_display":"635,665","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-20","filed_date":"2018-12-21","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":10,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":10,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":10},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001660334","name":"Verrica Pharmaceuticals Inc.","url":"/issuer/0001660334","role":"Director","n_filings":4,"first_seen":"2019-01-07","last_seen":"2024-11-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001806310","name":"Taysha Gene Therapies, Inc.","url":"/issuer/0001806310","role":"Director","n_filings":1,"first_seen":"2023-08-16","last_seen":"2023-08-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001576885","name":"Acumen Pharmaceuticals, Inc.","url":"/issuer/0001576885","role":"Director","n_filings":1,"first_seen":"2021-07-08","last_seen":"2021-07-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001685071","name":"Dova Pharmaceuticals Inc.","url":"/issuer/0001685071","role":"Director","n_filings":1,"first_seen":"2018-12-21","last_seen":"2018-12-21"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001709418","retrieved_at":"2026-08-25T07:30:10+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}